GILD — GILEAD SCIENCES, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 882095 ·
Last close
$150.93
Market Cap
$187.15B
52W High
$154.51
52W Low
$105.84
ADV30
5,715,817
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — — — —
Mar 2026 6,960,000,000 5,515,000,000 2,692,000,000 2,021,000,000 56,278,000,000 7,628,000,000 32,847,000,000
Dec 2025 7,924,000,000 6,300,000,000 2,988,000,000 2,183,000,000 59,023,000,000 7,564,000,000 36,405,000,000
Sep 2025 7,769,000,000 6,200,000,000 3,497,000,000 3,052,000,000 58,533,000,000 7,330,000,000 37,077,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$10,805,000,000
Investing CF
$-2,609,000,000
Financing CF
$-8,557,000,000
CapEx
$-576,000,000
Dividends Paid
$-4,033,000,000
Buybacks
$-1,611,000,000
EPS Diluted TTM
$-2.67
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$2,200,000,000
Inventory
$1,953,000,000
Receivables
$5,055,000,000
ST Investments
$0
EBIT TTM
$-957,000,000
Pretax Income TTM
$-1,955,000,000
Interest Exp TTM
$998,000,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$30,456,999,936
EBITDA
$14,600,999,936
Free Cash Flow
$9,768,875,008
Enterprise Value
$199,486,357,504
Total Cash
$4,881,999,872
Total Debt
$26,246,000,640
Shares Out
1,239,955,155
Trailing EPS
$-2.64
Book Value
$9.53
ROE
-20.7%
ROA
14.1%
Div Yield
2.28%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 29,442,000,000 11,701,000,000 8,510,000,000 59,023,000,000 36,405,000,000 22,702,000,000 10,019,000,000
Dec 2024 28,754,000,000 10,596,000,000 480,000,000 58,995,000,000 39,749,000,000 19,330,000,000 10,828,000,000
Dec 2023 27,116,000,000 8,838,000,000 5,665,000,000 62,125,000,000 39,376,000,000 22,833,000,000 8,006,000,000
Dec 2022 27,281,000,000 10,974,000,000 4,592,000,000 63,171,000,000 41,962,000,000 21,240,000,000 9,072,000,000

TTM Snapshot

Revenues TTM
$28,305,000,000
NetIncome TTM
$6,537,000,000
OpCashFlow TTM
$0
Assets (Latest)
$59,023,000,000
Forward EPS
$9.89

Max Pain — expiry 2026-10-16

max pain strike: $140.00 · spot: $150.93 · call oi: 7,163 · put oi: 3,448
Expected Move to 2026-10-16: ±$8.74 (5.79%) — implied range $142.19 – $159.67 · ATM straddle on $150.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $224.15B $414.61 —
MRNA Moderna, Inc. $79.40B $198.88 —
ARGX ARGENX SE $59.67B $959.49 —
RVMD Revolution Medicines, Inc. $43.93B $204.97 —
BIIB BIOGEN INC. $33.63B $227.60 —

News headlines (Yahoo Finance, 1h cache)

Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?
2026-09-27 23:20 · Yahoo
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
2026-09-27 23:16 · Yahoo
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?
2026-09-27 23:12 · Yahoo
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own?
2026-09-27 23:09 · Yahoo
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
2026-09-22 22:00 · Yahoo
1 Cash-Producing Stock on Our Buy List and 2 We Find Risky
2026-09-22 09:49 · Yahoo
Why Morgan Stanley likes Gilead's HIV prevention play
2026-09-20 16:03 · Yahoo
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?
2026-09-20 04:17 · Yahoo
Gilead Strengthens HIV Growth Platform with Expanded Latin America Access
2026-09-18 16:51 · Yahoo
Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
2026-09-17 22:36 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.